TNG348
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TNG348, covering 2024-08-13 to 2024-08-13. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors [Phase 1, Phase 2]